CL2009001323A1 - Metodo que mide estabilidad de antigeno que comprende obtener una primera medicion por cromatografia liquida (hplc) del antigeno en una muestra, obtener una segunda medicion por hplc en una segunda muestra, y cuantificar los cambios de la segunda medicion en comparacion a la primera por hplc. - Google Patents

Metodo que mide estabilidad de antigeno que comprende obtener una primera medicion por cromatografia liquida (hplc) del antigeno en una muestra, obtener una segunda medicion por hplc en una segunda muestra, y cuantificar los cambios de la segunda medicion en comparacion a la primera por hplc.

Info

Publication number
CL2009001323A1
CL2009001323A1 CL2009001323A CL2009001323A CL2009001323A1 CL 2009001323 A1 CL2009001323 A1 CL 2009001323A1 CL 2009001323 A CL2009001323 A CL 2009001323A CL 2009001323 A CL2009001323 A CL 2009001323A CL 2009001323 A1 CL2009001323 A1 CL 2009001323A1
Authority
CL
Chile
Prior art keywords
hplc
measurement
sample
antigen
obtaining
Prior art date
Application number
CL2009001323A
Other languages
English (en)
Inventor
Mark Williams
James Slightom
Frank Roerink
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of CL2009001323A1 publication Critical patent/CL2009001323A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/04—Preparation or injection of sample to be analysed
    • G01N2030/042—Standards
    • G01N2030/045—Standards internal
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/74—Optical detectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/86—Signal analysis
    • G01N30/8675—Evaluation, i.e. decoding of the signal into analytical information
    • G01N30/8679—Target compound analysis, i.e. whereby a limited number of peaks is analysed

Landscapes

  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

Método que mide estabilidad de antígeno que comprende obtener una primera medición por cromatografía líquida (HPLC) del antígeno en una muestra, obtener una segunda medición por HPLC en una segunda muestra, y cuantificar los cambios de la segunda medición en comparación a la primera por HPLC.
CL2009001323A 2008-05-30 2009-05-29 Metodo que mide estabilidad de antigeno que comprende obtener una primera medicion por cromatografia liquida (hplc) del antigeno en una muestra, obtener una segunda medicion por hplc en una segunda muestra, y cuantificar los cambios de la segunda medicion en comparacion a la primera por hplc. CL2009001323A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5734608P 2008-05-30 2008-05-30

Publications (1)

Publication Number Publication Date
CL2009001323A1 true CL2009001323A1 (es) 2009-10-23

Family

ID=40905178

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001323A CL2009001323A1 (es) 2008-05-30 2009-05-29 Metodo que mide estabilidad de antigeno que comprende obtener una primera medicion por cromatografia liquida (hplc) del antigeno en una muestra, obtener una segunda medicion por hplc en una segunda muestra, y cuantificar los cambios de la segunda medicion en comparacion a la primera por hplc.

Country Status (10)

Country Link
US (1) US20110091984A1 (es)
EP (1) EP2285461A1 (es)
JP (1) JP2011522252A (es)
AR (1) AR071931A1 (es)
BR (1) BRPI0913237A2 (es)
CA (1) CA2725450A1 (es)
CL (1) CL2009001323A1 (es)
MX (1) MX2010013148A (es)
TW (1) TW201009337A (es)
WO (1) WO2009146286A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11435351B2 (en) 2018-04-18 2022-09-06 Biomadison, Inc. Methods for determining vaccine potency

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2393298C (en) * 1999-12-02 2011-02-01 Chiron Corporation Compositions and methods for stabilizing biological molecules upon lyophilization
EP1913956A1 (en) 1999-12-02 2008-04-23 Novartis Vaccines and Diagnostics, Inc. Compositons and methods for stablizing biological molecules upon lyophilization
GB0406013D0 (en) * 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates

Also Published As

Publication number Publication date
US20110091984A1 (en) 2011-04-21
EP2285461A1 (en) 2011-02-23
AR071931A1 (es) 2010-07-28
JP2011522252A (ja) 2011-07-28
WO2009146286A1 (en) 2009-12-03
BRPI0913237A2 (pt) 2016-01-19
CA2725450A1 (en) 2009-12-03
MX2010013148A (es) 2011-03-21
TW201009337A (en) 2010-03-01

Similar Documents

Publication Publication Date Title
NZ596659A (en) Bulbless spectrometer
AR053948A1 (es) Deteccion de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapeutico correspondiente
CR20110567A (es) Dispositivos para diagnostico y metodos relacionados
CO2019012771A2 (es) Ensayos de diagnóstico para detectar, cuantificar y/o rastrear microbios y otros analitos
BR112016007106A2 (pt) dispositivo e método de teste de gravidez melhorado
AR054900A1 (es) Medidor con alarma de tiempo postprandial para efectuar determinaciones
CL2012002741A1 (es) Metodo para determinar en una muestra de sangre la presencia de vitamina d libre; inmunoensayo para detrminar presencia de vitamina d libre en sangre; kit para efectuar inmunoensayo.
CL2008003910A1 (es) Formulacion liquida, estable, conteniendo anticuerpo que comprende arginina y metionina; procedimiento para inhibir la deamidacion de moleculas de un anticuerpo que comprende agregar arginina a la formulacion liquida.
BR112013010952A2 (pt) sistemas de rmn e métodos para a detecção rápida de analisados
ATE493290T1 (de) Alcotestgerät
ES2570632T3 (es) Procedimiento de determinación del inhibidor de elastasa de leucocito in vitro del cáncer colorrectal
DK2155185T3 (da) Påvisning af succinylacetone
ES2674177T3 (es) Preparación de suero
BR112012021590A2 (pt) detecção de capacitância em ensaio eletroquímico
CL2011002973A1 (es) Metodo para detectar anticuerpos en una muestra que comprende contactar una muestra con un soporte que tiene fijado un peptoide; kit para detectar anticuerpos que son indicativos de una enfermedad neurodegenerativa.
BR112016024730A2 (pt) dispositivo, método e conjunto de análise imunocromatográfica
DK2118666T3 (da) Fremgangsmåde til normalisering af koncentrationen af analytter i en urinprøve
ES2684758T3 (es) Procedimiento para diagnosticar fibrosis hepática
BR112014032916A2 (pt) anticorpos anti-fármacos e usos destes para o monitoramento de fármaco
AR059361A1 (es) Dispositivo y metodos para detectar y cuantificar uno o mas agentes objetivos
BR112017027601A2 (pt) método de tomografia de poço cruzado, sistema para imagear uma formação de subsuperfície e método para obter informações sobre uma formação de subsuperfície
EA201400571A1 (ru) Специфичные к трансресвератролу антитела и их применение
AR112996A1 (es) Métodos de evaluación de conjugados de anticuerpo-fármaco
ES2578160T3 (es) Procedimiento de diagnóstico de infecciones de sitio quirúrgico
CL2009001323A1 (es) Metodo que mide estabilidad de antigeno que comprende obtener una primera medicion por cromatografia liquida (hplc) del antigeno en una muestra, obtener una segunda medicion por hplc en una segunda muestra, y cuantificar los cambios de la segunda medicion en comparacion a la primera por hplc.